18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
NCT06706921
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid)positron emission tomography/computed tomography , as per standard of care in our…
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Metastatic Prostate Cancer
- Male Urogenital Diseases
- Prostatic Diseases
- Urogenital Diseases, Male
- Genital Diseases, Male
- Neoplasms
- Neoplasms by Site
- Urogenital Neoplasms
- Genital Neoplasms, Male
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- VA Greater Los Angeles Healthcare System
- Last updated on ClinicalTrials.gov
- November 27, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- VA Greater Los Angeles Healthcare System · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.